| Basics |
Kura Oncology, Inc.
Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers.
|
| IPO Date: |
September 16, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$485.68M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.39 | 2.81%
|
| Avg Daily Range (30 D): |
$0.17 | 2.77%
|
| Avg Daily Range (90 D): |
$0.21 | 2.96%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.47M |
| Avg Daily Volume (30 D): |
.93M |
| Avg Daily Volume (90 D): |
1.12M |
| Trade Size |
| Avg Trade Size (Sh.): |
91 |
| Avg Trade Size (Sh.) (30 D): |
85 |
| Avg Trade Size (Sh.) (90 D): |
90 |
| Institutional Trades |
| Total Inst.Trades: |
2,786 |
| Avg Inst. Trade: |
$1.86M |
| Avg Inst. Trade (30 D): |
$1.17M |
| Avg Inst. Trade (90 D): |
$1.59M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.03M |
| Avg Closing Trade (30 D): |
$1.03M |
| Avg Closing Trade (90 D): |
$1.28M |
| Avg Closing Volume: |
127.83K |
|
|
|
|
| Financials |
| |
TTM |
Q3 2024 |
Q2 2024 |
|
Basic EPS
|
$-.66
|
$-.63
|
$-.59
|
|
Diluted EPS
|
$-.66
|
$-.63
|
$-.59
|
|
Revenue
|
$ 14.11M
|
$
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -57.43M
|
$ -54.4M
|
$ -50.84M
|
|
Operating Income / Loss
|
$ -64.7M
|
$
|
$
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -173.19M
|
$ 4.3M
|
$ 3.68M
|
|
PE Ratio
|
|
|
|
|
